中文摘要：
脂質納米顆粒 （LNP） 是基于 mRNA 的療法的非病毒遞送載體。人們在優化可電離脂質 （IL） 結構方面投入了大量精力，該結構包含與脂質尾部共軛的胺核，因為微小的分子調整會導致所得 LNP 的整體功效發生重大變化。然而，盡管取得了一些進展，但 LNP 遞送的一個主要障礙是內體逃逸。在這里，我們開發了一個平臺來合成一類改善內體逃逸的分支 IL。與非支鏈脂質相比，這些化合物包含末端支鏈基團，可增加肝臟 mRNA 和核糖核蛋白復合物的遞送和基因編輯效率以及 T 細胞轉染。通過一系列互補實驗，我們確定我們的脂質結構誘導更大的內體滲透和破壞。這項工作提供了一種為 mRNA 和蛋白質遞送生成一類 IL 的方案。
英文摘要：
Lipid nanoparticles (LNPs) are the preeminent non-viral drug delivery vehicle for mRNA-based therapies. Immense effort has been placed on optimizing the ionizable lipid (IL) structure, which contains an amine core conjugated to lipid tails, as small molecular adjustments can result in substantial changes in the overall efficacy of the resulting LNPs. However, despite some advancements, a major barrier for LNP delivery is endosomal escape. Here, we develop a platform for synthesizing a class of branched ILs that improve endosomal escape. These compounds incorporate terminally branched groups that increase hepatic mRNA and ribonucleoprotein complex delivery and gene editing efficiency as well as T cell transfection compared to non-branched lipids. Through an array of complementary experiments, we determine that our lipid architecture induces greater endosomal penetration and disruption. This work provides a scheme to generate a class of ILs for both mRNA and protein delivery.
論文信息：
論文題目：
Branched endosomal disruptor (BEND) lipids mediate delivery of mRNA and CRISPR-Cas9 ribonucleoprotein
complex for hepatic gene editing and T cell engineering
期刊名稱：Nature Communications
時間期卷：volume 16, Article number: 996 (2025)
在線時間：2025年1月24日
DOI：doi.org/10.1038/s41467-024-55137-6
產品信息：
貨號：CP-005-005
規格：5ml+5ml
品牌：Liposoma
產地：荷蘭
名稱：Clodronate Liposomes and Control Liposomes
辦事處：Target Technology（靶點科技）
Clodronate Liposomes氯膦酸鹽脂質體助力脂質納米顆粒 （LNP）遞送研究，荷蘭Liposoma巨噬細胞清除劑Clodronate Liposomes見刊于Nature Communications：
Clodronate Liposomes氯膦酸鹽脂質體清除肝臟Kuffer巨噬細胞文獻參考解決方案
Liposoma巨噬細胞清除劑Clodronate Liposomes氯膦酸二鈉脂質體的材料和方法：
Kupffer cells from C57BL/6J female mice, 6–8 weeks old, were depleted by administering 0.2?mL of clodronate liposomes (Liposoma, Amsterdam, Netherlands) at a dose of 5?mg/mL via the lateral tail vein. After 24?h, the mice were reinjected via the lateral tail vein with LNPs encapsulated FLuc at a dose of 0.1?mg/kg. After 12?h, liver luminescence was quantified as described above.
